DNA Vaccine for Treating and Preventing Type 1 Diabetes

USPTO granted Patent US12589141B2 to The Fifth Medical Center of Chinese PLA General Hospital for a DNA vaccine using a B7-2-PE40 exotoxin fusion gene to treat Type 1 Diabetes. The patent, with 10 claims, covers reduction of blood glucose, restoration of insulin secretion, and reduction of islet cell autoantibody (ICA) and glutamate decarboxylase autoantibody (GAD) levels. The application was filed on March 2, 2020.

Viral vectors with RDH12 coding regions for treating retinal dystrophies

The USPTO granted Patent US12589136B2 to The Regents of the University of Michigan covering viral vectors comprising RDH12 coding regions and methods of using such vectors to treat retinal dystrophies, including Leber Congenital Amaurosis. The patent, with 12 claims, names Debra A. Thompson, Robin R. Ali, and Alexander J. Smith as inventors. The patent covers nucleic acids encoding human RDH12 protein and their use in gene therapy applications for ophthalmological conditions caused by loss-of-function mutations.

Aloe vera polysaccharide antimicrobial composition patent grant

USPTO granted Patent US12589130B2 to 2QR RESEARCH B.V. on March 31, 2026. The patent covers Aloe vera polysaccharide compositions with antimicrobial aggregating activity, having molecular weight of 30-100 kDa and comprising 80-100% w/w mannose. Inventors are Floris Koumans and Paul Kwakman. The patent has 14 claims.

Bacteriophages for treatment of tuberculosis

USPTO granted Patent US12589127B2 to the University of Pittsburgh for pharmaceutical compositions comprising five or more bacteriophages designed to treat Mycobacterium tuberculosis infections. The patent covers methods of treating drug-resistant TB and preventing activation of latent TB disease, with 20 claims covering the phage combinations and treatment methods.

Anaerostipes caccae Compositions for Treating Allergic and Autoimmune Diseases

USPTO granted Patent US12589122B2 to the University of Chicago on March 31, 2026, covering compositions and methods for treating infectious, autoimmune, allergic diseases, and food allergies using the bacterium Anaerostipes caccae. The patent includes methods for reducing allergic responses and preventing anaphylactic responses, with claims extending to compositions comprising the bacterium with prebiotics.

Treatment of cachexia using fibroblast cells and products thereof

USPTO granted patent US12589119B2 to Fibrobiologics, Inc. covering methods and compositions for treating cachexia using immune-modulating fibroblasts. Inventors Pete O'Heeron and Thomas Ichim disclosed compositions including immune-modulating fibroblasts for treatment, amelioration, or prevention of cachexia or inflammation related to cachexia. The patent contains 12 claims.

Phenylethynyl-thiophene compounds for treating degenerative disorders

The USPTO granted patent US12589090B2 to Aquilus Pharmaceuticals, Inc. covering phenylethynyl-thiophene compounds that inhibit caspase 3 for treating degenerative disorders including ALS, Huntington's disease, epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. The patent claims 2 compounds and methods for their use.

Elafibranor treats Primary Biliary Cholangitis, Genfit patent

Elafibranor treats Primary Biliary Cholangitis, Genfit patent

Crypto-Backed Mortgage Product Saleable to Fannie Mae

A digital asset exchange (Coinbase) partnered with an online mortgage lender to announce the launch of what they described as the first U.S. mortgage product allowing borrowers to pledge cryptocurrency assets (Bitcoin or USDC) as down payment collateral while being saleable to Fannie Mae. Under the product structure, borrowers receive two loans at closing: a standard Fannie Mae mortgage on the home and a separate loan covering the down payment secured by pledged crypto. The companies characterized this as integration of crypto into the U.S. housing finance system.

Draft FY 2026-2030 Strategic Plan for Public Comment

The CFPB published a draft strategic plan for fiscal years 2026-2030 outlining three goals: addressing consumer threats, reducing regulatory burdens, and strengthening governance. The plan emphasizes fraud protection, servicemember protections, partnering with DOJ on debanking issues, and implementing Executive Order 14219 to rescind burdensome regulations. Public comments are due April 17, 2026.

Fannie Mae and Freddie Mac Revise Insurance and Condo Requirements

FHFA directed Fannie Mae and Freddie Mac to revise selling and servicing guide requirements for homeowners insurance and condominium project reviews. Key insurance changes include retirement of lender documentation requirements for replacement cost value on one-to-four-unit properties and permitting actual cash value coverage for roofs, with a $50,000 per-unit deductible cap. Condominium reserve requirements increase from 10% to 15% of annual budgeted assessment income, streamlined review exemptions expand to projects with up to 10 units, and Florida's separate condo project approval process is eliminated. Insurance changes took effect immediately while project review changes phase through early 2027.

FinCEN Targets MBaer with Most Severe Section 311 Measure

FinCEN issued a Notice of Proposed Rulemaking designating MBaer Merchant Bank AG a 'primary money laundering concern' under Section 311 of the PATRIOT Act. The proposed special measure five would effectively ban MBaer from the U.S. financial system by preventing U.S. financial institutions from maintaining correspondent accounts for the Swiss-based bank. FinCEN alleges MBaer facilitated Venezuelan corruption, Russian and Iranian money laundering, and terrorist financing.

Executive Order to Expand Mortgage Credit Access

The White House issued Executive Order "Promoting Access to Mortgage Credit" directing the CFPB, Fed, FDIC, FHFA, NCUA, OCC, HUD, VA, and USDA to consider actions reducing mortgage lending compliance burdens under Dodd-Frank. The order specifically targets relief for banks under $100 billion in assets and aims to reverse declining bank participation in mortgage lending by modernizing ATR/QM requirements, TILA-RESPA disclosure timing, appraisal regulations, and supervisory guidance.

CFTC Innovation Task Force for Derivatives

CFTC Chair Michael Selig announced formation of the Innovation Task Force on March 24, 2026, dedicated to advancing clear rules for companies building novel products and technologies within U.S. derivatives markets. The task force will partner with the CFTC's Innovation Advisory Committee and coordinate with the SEC's Crypto Task Force on innovation initiatives.

SEC and CFTC Sign Historic Digital Assets MOU

The SEC and CFTC signed a Memorandum of Understanding on March 11, 2026, establishing a coordination framework across six key areas including digital assets, product definitions, and dually registered firms. The MOU supersedes the 2018 agreement and introduces data sharing, advance notification procedures, cross-training, and senior-level coordination mechanisms. The agreement signals a shift from enforcement-first regulation toward a 'minimum effective dose' philosophy for digital assets.

NOVOSEVEN Registered Trademark for Factor VIIa Hemophilia Treatment

USPTO has registered the trademark NOVOSEVEN (Registration No. TM74546941) for a Factor VIIa pharmaceutical preparation used in hemophilia treatment. The trademark was registered on March 30, 2026, with an original filing date of July 7, 1994. This is an informational trademark registration notice with no new compliance requirements.

PAC Hearing on Government Outstanding Claims and Commitments

The Public Accounts Committee of Parliament of Ghana held a hearing on March 3, 2026, where ministries appeared to respond to the Auditor-General's Special Audit Report on Government Outstanding Claims and Commitments as of December 31, 2024. The Committee, chaired by Hon. Abena Osei Asare, identified gaps in the report's integrity details and proposed that the Ministry of Finance review Volumes One and Two to address omissions.

New Presidential Pardon Review Approach

The Irish Minister for Justice, Séamus Ó Ceallacháin, has received in-principle Government approval for a new approach to reviewing presidential pardon applications. Under this policy, only convictions imposed after the establishment of the Irish State in 1922 will be eligible for presidential pardon consideration going forward. This addresses longstanding difficulties with historical cases that predate Irish independence and were under British jurisdiction.

Hamidah NABAGALA added to UN sanctions list

The Guernsey Financial Services Commission issued a notice that the UN Security Council Committee pursuant to Resolution 1267 has added Hamidah NABAGALA (QDi.439) to the ISIL (Da'esh) and Al-Qaida Sanctions List. All businesses in Guernsey must immediately screen for relationships with the newly designated individual, freeze any associated funds or assets, and report findings to the Policy & Resources Committee.

WATERDROP Trade Mark Opposition - Dilution, Reputation and Proof of Use

The UK Intellectual Property Office Appointed Person Dr. Brian Whitehead issued Decision O/0275/26 concerning the WATERDROP trade mark. The decision addressed five marks including word and figurative variations. Multiple grounds were considered under Sections 5(1), 5(2), and 5(3) relating to dilution by blurring and tarnishment, Section 5(4) on passing off, and proof of use requirements for revocation.

Storey v AXA XL Insurance Company UK Ltd - Costs Recovery

The County Court of Northern Ireland (Londonderry District Judge) issued a judgment on 26 March 2026 in Storey v AXA XL Insurance Company UK Ltd regarding costs recovery under Order 21 Rule 2(1) of the County Court Rules. The case arose from a road traffic accident claim where the plaintiff accepted an £8,750 lodgment in settlement but disputed costs. The court determined the plaintiff's entitlement to costs where the professional fee is marked at full scale for the settlement amount.

Fisher v Tughans - Defamation Strike-Out Application Denied

Master Bell of the Northern Ireland High Court denied Tughans Solicitors' application to strike out three defamation actions. The actions arise from emails sent in 2019 during a conveyancing transaction where plaintiffs allege defamatory statements about solicitor fees. The Master rejected the strike-out requests under Order 18 Rule 19(1)(c) and (d) and Section 8 of the Defamation Act 1996.

McGee v Morag Finance - Mortgage Repossession Injunction

The High Court of Justice in Northern Ireland, Chancery Division dismissed an application by the McGees seeking an interim injunction to prevent Morag Finance Limited from selling their former home at 9 Clontycarty Lane, Tynan, Armagh. The court also ordered disclosure of documents by the respondent. This decision continues 16 years of litigation stemming from a 2009 possession order originally obtained by Amber Homeloans Limited.

R v Maguire - Domestic Abuse Sentencing Appeal

The Court of Appeal in Northern Ireland dismissed an appeal against sentence for domestic abuse offences. The appellant Barry Maguire challenged the five-year determinate custodial sentence (split custody/licence) imposed for counts including domestic abuse contrary to section 1 of the Domestic Abuse and Civil Proceedings Act (NI) 2021 and non-fatal strangulation contrary to section 28 of the Justice (Sexual Offences and Trafficking Victims) Act (NI) 2022. The court upheld the sentence, including the statutory domestic abuse aggravator uplift under section 15 of the 2021 Act.

Proposed Information Collection Changes for Export License Modifications

The State Department's Directorate of Defense Trade Controls (DDTC) issued a 30-day notice proposing changes to information collection requirements for requests to change end-user, end-use, and destination of hardware and Open General Licenses. The notice opens a public comment period ending April 30, 2026, seeking input on the proposed modifications to export license modification procedures.

Commodity Jurisdiction Determination Information Collection

The State Department published a 30-day notice seeking public comments on a proposed information collection for Commodity Jurisdiction Determination requests. This collection governs the process by which exporters and manufacturers determine whether items fall under State Department (ITAR) or Commerce Department (EAR) jurisdiction. The comment period closes April 30, 2026.

Technology Security/Clearance Plans Information Collection

The State Department has issued a 30-day notice seeking public comments on a proposed information collection related to technology security/clearance plans, screening records, and non-disclosure agreements pursuant to 22 CFR 126.18. The notice invites input from manufacturers, technology companies, and entities engaged in international trade involving controlled technology. Comments must be submitted by April 30, 2026.

Training Program for Interpreters Serving Deaf and Deafblind Individuals

The Education Department (ED) announces a competition for training interpreters serving individuals who are deaf, hard of hearing, or deafblind. The notice requests public comments on the proposed training program scope and requirements. Comments are due by May 26, 2026.

Child Care Access Means Parents in School Annual Performance Report Package

The Department of Education published a Federal Register notice on March 31, 2026, requesting public comments on the FY 2026 Child Care Access Means Parents in School (CCAMPIS) Annual Performance Report Package (84.335A). The notice solicits comments on the proposed information collection requirements for institutions receiving CCAMPIS grants. Comments must be submitted by June 1, 2026.

Option to tax property when cancelling VAT registration

HMRC published guidance for businesses cancelling their VAT registration on disclosing option to tax information for land and buildings. Businesses must provide property addresses, land registry title numbers, purchase dates, and details of previous and subsequent owners when submitting their deregistration request.

Liberty Global / Telefonica / Substantial Merger

The European Commission cleared the Liberty Global/Telefonica/Substantial merger under the super-simplified procedure. The Commission issued a non-opposition decision under Article 6(1)(b) on March 30, 2026, before the provisional Phase 1 deadline of April 8, 2026. The transaction involves telecommunications operators operating under NACE Rev. 2.1 code K.61.10.

Liberty Global / Telefonica / Infravia / Netomnia and BRSK Merger

The European Commission granted Phase 1 clearance to the Liberty Global / Telefonica / Infravia / Netomnia and BRSK Assets concentration under the super-simplified procedure. The decision (Art. 6(1)(b)) was issued on March 30, 2026. The case falls under Council Regulation (EC) No 139/2004 and involves wired, wireless, and satellite telecommunications activities (NACE K.61.10).

US v. Roache - Criminal Appeal

The First Circuit issued an opinion in US v. Roache (Docket 25-1157), a criminal appeal from the District of Massachusetts. The court affirmed, reversed, or remanded the lower court's decision. This appellate ruling establishes binding precedent within the First Circuit's jurisdiction.

Roache v. United States - Firearms Trafficking Sentencing Appeal

The 1st Circuit affirmed the District of Massachusetts's judgment sentencing Aizavier Roache to 57 months imprisonment plus 3 years supervised release for firearms trafficking conspiracy under 18 U.S.C. § 933(a)(1), (3). The court rejected Roache's challenge to a 6-point sentencing guideline enhancement based on co-conspirator statements to ATF agents.

Coleman sues Archer Aviation, civil rights jobs complaint

Coleman sues Archer Aviation, civil rights jobs complaint

Letters of Caution to X and TikTok for Online Safety Failures

IMDA issued Letters of Caution to X and TikTok placing both platforms under Enhanced Supervision after finding serious weaknesses in their content moderation. X saw a 120% increase in CSEM cases with Singapore nexus (33 to 73 cases), while TikTok had 17 terrorism content cases from Singapore-based accounts in 2025. Both platforms must demonstrate effectiveness of rectification measures by 30 June 2026.

Lipella Pharmaceuticals - Chapter 11 Bankruptcy Filing Disclosure

Lipella Pharmaceuticals Inc. filed a Form 8-K with the SEC disclosing that the company and certain subsidiaries filed voluntary petitions for Chapter 11 bankruptcy relief in the United States Bankruptcy Court for the Western District of Pennsylvania on March 30, 2026. The filing is required under Item 1.03 of Form 8-K to report material events affecting the registrant. The company cautions that trading in its common stock during the pendency of the Chapter 11 case is highly speculative.

Knee brace design patent

The USPTO granted Design Patent USD1121161S1 to Shock Doctor, Inc. for an ornamental knee brace design. The patent was issued on March 31, 2026, based on application No. 29944597 filed on May 29, 2024. The patent contains one design claim covering the visual appearance of the knee brace.

Low profile transcatheter heart valve

USPTO issued patent grant US12588987B2 to Edwards Lifesciences Corporation on March 31, 2026, covering a low profile transcatheter heart valve prosthetic. The invention includes a radially collapsible and expandable annular frame with three commissure attachment posts, four rows of circumferential struts, and a three-leaflet structure.

Knee Brace Design

The USPTO granted design patent USD1121163S1 for a knee brace to Guangdong Transcontinental Technology Co., Ltd. The patent covers the ornamental design of the knee brace with one claim. Filing date was December 5, 2024, and the grant date is March 31, 2026.

Penile sleeve implant patent granted to Loria Cosmetic Urology

USPTO granted Design Patent USD1121151S1 to Loria Cosmetic Urology LLC for a penile sleeve implant. The patent was issued on March 31, 2026, with Victor Loria listed as the sole inventor and one design claim. CPC classifications indicate the device falls under male reproductive system medical devices (A61F 2/26, A61F 5/41).

Thumb brace design patent

USPTO issued Design Patent USD1121164S1 to Dongguan Feibu Industrial Co., Ltd. for a thumb brace. The patent, with a single claim, was granted March 31, 2026, based on application filed January 14, 2025.

Compliant Biological Scaffold with Biaxial Expansion

USPTO granted patent US12588985B2 to inventor Brent Schultz for a compliant biological scaffold incorporating elongated apertures arranged in geometric patterns that enable biaxial expansion or contraction. The scaffold may be formed in biological material in vivo or ex vivo and has applications in prosthetics and medical implants. The patent contains 25 claims and is classified under CPC codes A61F 2/86, A61F 2/90, and A61F 2/0063.

Peptide-derived KDM5C targeting cancer therapeutics patent grant

USPTO granted Patent US12589160B2 to NUVOBIO CORPORATION covering peptide-derived therapeutics targeting KDM5C for cancer treatment. The patent, filed on March 12, 2020, contains 6 claims and names inventors Kyle Kevin Biggar, Hemanta Adhikary, and Matthew Jacob Hoekstra. This grant establishes exclusive intellectual property rights for the assignee in the United States.

Multivalent HVT vector vaccine for poultry

USPTO granted Patent US12589147B2 to Intervet Inc. for a recombinant herpesvirus of turkeys (rHVT) vector vaccine expressing antigens from IBDV, NDV, and AIV. The patent covers 20 claims and can be used to vaccinate poultry against four diseases: MDV, IBDV, NDV, and AIV simultaneously.

HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas

The USPTO granted Patent US12589142B2 to PMCR GmbH covering pharmaceutical compositions comprising HLA-A tumor antigen peptides (4-8 peptides for MHC class I and 2+ for MHC class II) for treating breast carcinomas. The patent includes 4 claims and covers methods for preparing the composition and determining HLA peptides.

Ruxolitinib formulation for reduction of itch in atopic dermatitis

USPTO granted Patent US12589096B2 to Incyte Corporation on March 31, 2026. The patent covers a topical 0.75% or 1.5% ruxolitinib cream formulation administered two times per day for reducing itch in patients with atopic dermatitis. The patent includes 20 claims and names Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, and Jim Lee as inventors.

Glucocorticoid receptor modulator relacorilant with paclitaxel patent granted

USPTO granted patent US12589094B2 to Corcept Therapeutics Incorporated on March 31, 2026, covering methods of co-administering glucocorticoid receptor modulator relacorilant with paclitaxel by reducing paclitaxel dose to approximately half when used together. The patent addresses drug-drug interaction management, noting that despite in vitro predictions of 5-fold increased paclitaxel exposure, in vivo co-administration showed only 80% increase, enabling a safer combination therapy for treating cancers such as ovarian and pancreatic.

C2-C7 alkyl boronic acids as antimicrobial antiviral therapeutic compounds

USPTO granted patent US12589103B2 to Cornell University covering methods for treating bacteria and viruses using C2-C7 alkyl boronic acids to reduce growth and virulence. The patent, filed October 7, 2020, names inventors Kenneth W. Simpson, Shiying Zhang, and Michael Fischbach and contains 28 claims.

Injectable sustained-release formulations for treatment of joint pain and inflammation

USPTO granted patent US12589102B2 to FORDOZ Pharma Corp. covering injectable drug-loaded microspheres combining steroidal and non-steroidal anti-inflammatory drugs for sustained release. The patent also protects methods of making the microspheres and using them to treat rheumatoid arthritis and osteoarthritis. The patent contains 9 claims and names inventors Sydney Ugwu, James He, and Zengli Fu.